<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Boston Scientific Corp — News on 6ix</title>
<link>https://6ix.com/company/boston-scientific-corp</link>
<description>Latest news and press releases for Boston Scientific Corp on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Sun, 26 Apr 2026 17:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/boston-scientific-corp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835504a78dffbe2df0e7236.webp</url>
<title>Boston Scientific Corp</title>
<link>https://6ix.com/company/boston-scientific-corp</link>
</image>
<item>
<title>Data at Heart Rhythm 2026 highlight key Boston Scientific therapies</title>
<link>https://6ix.com/company/boston-scientific-corp/news/data-at-heart-rhythm-2026-highlight-key-boston-scientific-therapies</link>
<guid isPermaLink="true">https://6ix.com/company/boston-scientific-corp/news/data-at-heart-rhythm-2026-highlight-key-boston-scientific-therapies</guid>
<pubDate>Sun, 26 Apr 2026 17:00:00 GMT</pubDate>
<description>Boston Scientific Corporation (NYSE: BSX) today announced data supporting use of the company's FARAPULSE™ Pulsed Field Ablation (PFA) Platform and WATCHMAN™ Left Atrial Appendage Closure (LAAC) technologies. All data were presented at Heart Rhythm 2026, the annual meeting of the Heart Rhythm Society, held in Chicago from April 24-26.</description>
</item>
<item>
<title>Boston Scientific announces results for first quarter 2026</title>
<link>https://6ix.com/company/boston-scientific-corp/news/boston-scientific-announces-results-for-first-quarter-2026</link>
<guid isPermaLink="true">https://6ix.com/company/boston-scientific-corp/news/boston-scientific-announces-results-for-first-quarter-2026</guid>
<pubDate>Wed, 22 Apr 2026 10:30:00 GMT</pubDate>
<description>Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.203 billion during the first quarter of 2026, growing 11.6 percent on a reported basis and 9.4 percent on an operational1 and organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $1.341 billion or $0.90 per share (EPS), compared to $674 million or $0.45 per share a year ago, and achieved adjusted3 EPS of $0.80 for the period, compared</description>
</item>
<item>
<title>Boston Scientific announces conference call discussing first quarter 2026 results</title>
<link>https://6ix.com/company/boston-scientific-corp/news/boston-scientific-announces-conference-call-discussing-first-quarter-2026-results</link>
<guid isPermaLink="true">https://6ix.com/company/boston-scientific-corp/news/boston-scientific-announces-conference-call-discussing-first-quarter-2026-results</guid>
<pubDate>Mon, 30 Mar 2026 12:00:00 GMT</pubDate>
<description>Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2026, on Wednesday, April 22, 2026, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Jon Monson, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the first quarter on April 22 prior to the conference call.</description>
</item>
<item>
<title>CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints</title>
<link>https://6ix.com/company/boston-scientific-corp/news/champion-af-study-of-the-watchman-flxtm-left-atrial-appendage-closure-device-as-a-first-line-therapy-for-stroke-risk-reduction-meets-all-primary-and-secondary-safety-and-efficacy-endpoints</link>
<guid isPermaLink="true">https://6ix.com/company/boston-scientific-corp/news/champion-af-study-of-the-watchman-flxtm-left-atrial-appendage-closure-device-as-a-first-line-therapy-for-stroke-risk-reduction-meets-all-primary-and-secondary-safety-and-efficacy-endpoints</guid>
<pubDate>Sat, 28 Mar 2026 14:55:00 GMT</pubDate>
<description>Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary safety and efficacy endpoints. The study evaluated the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device compared to non-vitamin K antagonist oral anticoagulants (NOACs) as a first-line option for stroke risk reduction in a broad population of patients with non-valvular atrial fibrillation (NVAF). Key results were presented as a late-breaking clinical trial a</description>
</item>
<item>
<title>HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism</title>
<link>https://6ix.com/company/boston-scientific-corp/news/hi-peitho-trial-demonstrates-boston-scientific-ekostm-endovascular-system-is-superior-to-standard-of-care-for-treatment-of-acute-pulmonary-embolism</link>
<guid isPermaLink="true">https://6ix.com/company/boston-scientific-corp/news/hi-peitho-trial-demonstrates-boston-scientific-ekostm-endovascular-system-is-superior-to-standard-of-care-for-treatment-of-acute-pulmonary-embolism</guid>
<pubDate>Sat, 28 Mar 2026 14:38:00 GMT</pubDate>
<description>Boston Scientific Corporation (NYSE: BSX) today announced positive data from the HI-PEITHO global randomized clinical trial evaluating the use of the EKOS™ Endovascular System in patients with intermediate-risk pulmonary embolism (PE). The study met the composite primary endpoint, with data demonstrating that the EKOS system plus anticoagulation was superior to the current standard of care – anticoagulation alone – for the treatment of acute PE. Findings from the trial were presented in a late-b</description>
</item>
<item>
<title>Boston Scientific to host investor event at the 75th Annual Scientific Session of the American College of Cardiology</title>
<link>https://6ix.com/company/boston-scientific-corp/news/boston-scientific-to-host-investor-event-at-the-75th-annual-scientific-session-of-the-american-college-of-cardiology-35</link>
<guid isPermaLink="true">https://6ix.com/company/boston-scientific-corp/news/boston-scientific-to-host-investor-event-at-the-75th-annual-scientific-session-of-the-american-college-of-cardiology-35</guid>
<pubDate>Fri, 06 Mar 2026 13:00:00 GMT</pubDate>
<description>Boston Scientific Corporation (NYSE: BSX) will host an investor event and live webcast on Saturday, March 28, 2026, at 6:30 p.m. ET / 5:30 p.m. CT to discuss key clinical data presented earlier that day at the 75th Annual Scientific Session of the American College of Cardiology. The event will be hosted by Dr. Kenneth Stein, senior vice president and global chief medical officer, Dr. Brad Sutton, chief medical officer, AF solutions and Dr. Michael R. Jaff, vice president and chief medical office</description>
</item>
<item>
<title>Boston Scientific elects Cathy Smith and Christophe Weber to Board of Directors</title>
<link>https://6ix.com/company/boston-scientific-corp/news/boston-scientific-elects-cathy-smith-and-christophe-weber-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/boston-scientific-corp/news/boston-scientific-elects-cathy-smith-and-christophe-weber-to-board-of-directors</guid>
<pubDate>Mon, 23 Feb 2026 13:00:00 GMT</pubDate>
<description>Boston Scientific Corporation (NYSE: BSX) announced today the election of Cathy Smith and Christophe Weber to its Board of Directors, effective February 18, 2026.</description>
</item>
<item>
<title>Boston Scientific to participate in TD Cowen's 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/boston-scientific-corp/news/boston-scientific-participate-td-cowens-130000622</link>
<guid isPermaLink="true">https://6ix.com/company/boston-scientific-corp/news/boston-scientific-participate-td-cowens-130000622</guid>
<pubDate>Fri, 13 Feb 2026 13:00:00 GMT</pubDate>
<description>Boston Scientific Corporation (NYSE: BSX) will participate in TD Cowen's 46th Annual Health Care Conference on Tuesday, March 3, 2026. Mike Mahoney, chairman and chief executive officer, and Kenneth Stein, M.D., senior vice president and global chief medical officer, will participate in a 30-minute question-and-answer session with the host analyst at approximately 9:10 a.m. ET.</description>
</item>
<item>
<title>Boston Scientific announces results for fourth quarter and full year 2025</title>
<link>https://6ix.com/company/boston-scientific-corp/news/boston-scientific-announces-results-fourth-113000932</link>
<guid isPermaLink="true">https://6ix.com/company/boston-scientific-corp/news/boston-scientific-announces-results-fourth-113000932</guid>
<pubDate>Wed, 04 Feb 2026 11:30:00 GMT</pubDate>
<description>Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported basis, 14.3 percent on an operational1 basis and 12.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $672 million or $0.45 per share (EPS), compared to $566 million or $0.38 per share a year ago, and achieved adjusted3 EPS of $0.80 fo</description>
</item>
<item>
<title>Boston Scientific announces agreement to acquire Penumbra, Inc.</title>
<link>https://6ix.com/company/boston-scientific-corp/news/boston-scientific-announces-agreement-acquire-120000564</link>
<guid isPermaLink="true">https://6ix.com/company/boston-scientific-corp/news/boston-scientific-announces-agreement-acquire-120000564</guid>
<pubDate>Thu, 15 Jan 2026 12:00:00 GMT</pubDate>
<description>Boston Scientific Corporation (NYSE: BSX) and Penumbra, Inc., (NYSE: PEN) today announced the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock transaction that values Penumbra at $374 per share, reflecting an enterprise value of approximately $14.5 billion.i</description>
</item>
<item>
<title>Boston Scientific Announces Agreement to Acquire Valencia Technologies Corporation</title>
<link>https://6ix.com/company/boston-scientific-corp/news/boston-scientific-announces-agreement-acquire-120000004</link>
<guid isPermaLink="true">https://6ix.com/company/boston-scientific-corp/news/boston-scientific-announces-agreement-acquire-120000004</guid>
<pubDate>Mon, 12 Jan 2026 12:00:00 GMT</pubDate>
<description>Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Valencia Technologies Corporation, a privately held medical technology company focused on the development and commercialization of innovative solutions to treat bladder dysfunction. The company's eCoin® System is an implantable tibial nerve stimulation (ITNS) device for the treatment of urge urinary incontinence (UUI), a common symptom of overactive bladder (OAB).</description>
</item>
<item>
<title>Boston Scientific announces participation in the J.P. Morgan Healthcare Conference and conference call discussing fourth quarter and full year 2025 results</title>
<link>https://6ix.com/company/boston-scientific-corp/news/boston-scientific-announces-participation-j-130000046</link>
<guid isPermaLink="true">https://6ix.com/company/boston-scientific-corp/news/boston-scientific-announces-participation-j-130000046</guid>
<pubDate>Fri, 02 Jan 2026 13:00:00 GMT</pubDate>
<description>Boston Scientific Corporation (NYSE: BSX) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13th, 2026, in San Francisco. Mike Mahoney, chairman and chief executive officer, Jon Monson, executive vice president and chief financial officer, and Ken Stein, M.D., senior vice president and global chief medical officer, will participate in a 40-minute question-and-answer session with the host analyst. The session will begin at approximately 9:00 a.m. PT / 12:00</description>
</item>
<item>
<title>Boston Scientific announces upcoming investor conference schedule</title>
<link>https://6ix.com/company/boston-scientific-corp/news/boston-scientific-announces-upcoming-investor-130000306</link>
<guid isPermaLink="true">https://6ix.com/company/boston-scientific-corp/news/boston-scientific-announces-upcoming-investor-130000306</guid>
<pubDate>Mon, 03 Nov 2025 13:00:00 GMT</pubDate>
<description>Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences.</description>
</item>
<item>
<title>Boston Scientific announces results for third quarter 2025</title>
<link>https://6ix.com/company/boston-scientific-corp/news/boston-scientific-announces-results-third-103000002</link>
<guid isPermaLink="true">https://6ix.com/company/boston-scientific-corp/news/boston-scientific-announces-results-third-103000002</guid>
<pubDate>Wed, 22 Oct 2025 10:30:00 GMT</pubDate>
<description>Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.065 billion during the third quarter of 2025, growing 20.3 percent on a reported basis, 19.4 percent on an operational1 basis and 15.3 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $755 million or $0.51 per share (EPS), compared to $469 million or $0.32 per share a year ago, and achieved adjusted3 EPS of $0.75 for</description>
</item>
<item>
<title>Boston Scientific Announces Agreement to Acquire Nalu Medical, Inc.</title>
<link>https://6ix.com/company/boston-scientific-corp/news/boston-scientific-announces-agreement-acquire-110000318</link>
<guid isPermaLink="true">https://6ix.com/company/boston-scientific-corp/news/boston-scientific-announces-agreement-acquire-110000318</guid>
<pubDate>Fri, 17 Oct 2025 11:00:00 GMT</pubDate>
<description>Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Nalu Medical, Inc., a privately held medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic pain.</description>
</item>
<item>
<title>Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million</title>
<link>https://6ix.com/company/boston-scientific-corp/news/elutia-announces-closing-of-bioenvelope-business-sale-to-boston-scientific-corporation-for-dollar88-million</link>
<guid isPermaLink="true">https://6ix.com/company/boston-scientific-corp/news/elutia-announces-closing-of-bioenvelope-business-sale-to-boston-scientific-corporation-for-dollar88-million</guid>
<pubDate>Wed, 01 Oct 2025 12:41:00 GMT</pubDate>
<description>- Strengthened balance sheet to fully fund development and launch of NXT-41 platform - - Biologics for breast reconstruction represents $1.5 billion U.S. total addressable market - GAITHERSBURG, Md., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the closing of the sale of its BioEnvelope business, including the EluPro™ and CanGaroo® bioenvelopes, to Boston Scientific Corporation (NYSE: B</description>
</item>
<item>
<title>Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million</title>
<link>https://6ix.com/company/boston-scientific-corp/news/elutia-announces-sale-of-bioenvelope-business-to-boston-scientific-corporation-for-dollar88-million</link>
<guid isPermaLink="true">https://6ix.com/company/boston-scientific-corp/news/elutia-announces-sale-of-bioenvelope-business-to-boston-scientific-corporation-for-dollar88-million</guid>
<pubDate>Tue, 09 Sep 2025 12:30:00 GMT</pubDate>
<description>- Transaction affirms the strength of Elutia’s proprietary drug-eluting biologics platform and fully funds advancement of NXT-41 in breast reconstruction - - Company to provide update at the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10 at 9:30 a.m. ET - GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced it has entered into a definitiv</description>
</item>
<item>
<title>Boston Scientific announces 2025 Investor Day meeting and conference call discussing third quarter 2025 results</title>
<link>https://6ix.com/company/boston-scientific-corp/news/boston-scientific-announces-2025-investor-120000770</link>
<guid isPermaLink="true">https://6ix.com/company/boston-scientific-corp/news/boston-scientific-announces-2025-investor-120000770</guid>
<pubDate>Tue, 02 Sep 2025 12:00:00 GMT</pubDate>
<description>Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategies on Tuesday, September 30, 2025, beginning at 8:30 a.m. ET.</description>
</item>
<item>
<title>Boston Scientific announces results for second quarter 2025</title>
<link>https://6ix.com/company/boston-scientific-corp/news/boston-scientific-announces-results-second-103000104</link>
<guid isPermaLink="true">https://6ix.com/company/boston-scientific-corp/news/boston-scientific-announces-results-second-103000104</guid>
<pubDate>Wed, 23 Jul 2025 10:30:00 GMT</pubDate>
<description>Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.061 billion during the second quarter of 2025, growing 22.8 percent on a reported basis, 21.6 percent on an operational1 basis and 17.4 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $797 million or $0.53 per share (EPS), compared to $324 million or $0.22 per share a year ago, and achieved adjusted3 EPS of $0.75 fo</description>
</item>
<item>
<title>Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System</title>
<link>https://6ix.com/company/boston-scientific-corp/news/boston-scientific-receives-fda-approval-110000692</link>
<guid isPermaLink="true">https://6ix.com/company/boston-scientific-corp/news/boston-scientific-receives-fda-approval-110000692</guid>
<pubDate>Mon, 07 Jul 2025 11:00:00 GMT</pubDate>
<description>Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use (IFU) labeling for the FARAPULSE™ Pulsed Field Ablation (PFA) System. The updated labeling now includes approval for the system in the treatment of drug refractory, symptomatic persistent atrial fibrillation (AF), an arrythmia in which the heart beats abnormally for at least seven days.</description>
</item>
</channel>
</rss>